Resources
189 Results (showing 61 - 70)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 8/23/2022 (updated 3/27/2024)
In this cross-sectional, multistate study of rural communities, 79% of people using drugs reported past-30-day methamphetamine use; nonfatal overdose was greatest in people using both methamphetamine and opioids (22%) vs opioids alone (14%), or methamphetamine alone (6%). People using both substances reported the least access to treatment; only 17% of those using methamphetamine alone had naloxone.
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 7/25/2022 (updated 3/27/2024)
In New York City (NYC), there were 2062 overdose fatalities in 2020, the deadliest year on record for NYC and the US. Fentanyl and its analogs were the most common substances involved in overdose deaths in NYC, present in 77% of such deaths in 2020. A characteristic of fentanyl-involved overdose is rapid onset of overdose symptoms; however, with timely administration of oxygen or naloxone, deaths can be averted.
Posted 7/25/2022 (updated 3/27/2024)
In 2019, the Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington launched the “Meds First” program to provide onsite, low-barrier access to buprenorphine in partnership with six syringe services programs across WA State. A key component of the Meds First service model was the addition of care navigation to support client engagement and retention in OUD treatment.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 6/27/2022 (updated 3/27/2024)
Naloxone leave behind programs are a popular public health intervention for combatting the opioid epidemic. These programs are designed for first responders to educate and equip high risk, nonmedical individuals to respond to opioid overdose scenarios. However, stigma and misconceptions regarding naloxone remain common among medical providers, including emergency medical services (EMS) members.
Posted 6/14/2022 (updated 3/27/2024)
Overdose education and naloxone distribution (OEND) to laypersons are key approaches to reduce the incidence of opioid-involved overdoses. While some research has examined attitudes toward OEND, especially among pharmacists and first responders, our understanding of what laypersons believe about overdose and naloxone is surprisingly limited.
Posted 6/7/2022 (updated 3/27/2024)
Cohort-Specific Sessions/Activities and Day 2 Wrap-Up
Posted 6/7/2022 (updated 3/27/2024)
This presentation featured an overview of epidemiology of stimulant use, describe toxicities of stimulant use, and identify interventions to address stimulant use.
Posted 6/7/2022 (updated 3/27/2024)
Dr. Brooklyn discussed the following topics: the implementation of a Hub and Spoke model can lead to a significant increase in number of people with OUD treated in rural areas by providing resources for small and rural medical and behavioral health practices and a novel program to increase dosing compliance and security through the use of secure medication dispensers and a Smartphone app can increase access to MOUD in rural areas.